Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
    2. Saint-Petersburg State Pediatric Medical University (St. Petersburg, Russian Federation)

    Keywords:Candidiasis,metabolic syndrome,treatment

    Abstract:The article presents modern principles of diagnostics and treatment of candidiasis of the upper digestive tract (oropharynx and esophagus) described the clinical picture and complications of this disease. Metabolic syndrome, occurring with disorders of carbohydrate metabolism - a typical risk factor for candidiasis. Standard for diagnosis is the detection of filamentous forms (pseudomycelium) of micromycetes of the genus Candida a morphological study of biomaterials mucous membrane. Culture of biopsy specimens with identification of the species of the pathogen becomes mandatory for maintaining tolerance to standard treatment or recurrent candidiasis. The drug of choice when treating candidiasis is fluconazole, however, in some cases, necessary alternative antimycotic drugs. Feature of the treatment of candidiasis in patients with the metabolic syndrome is an increased risk of drug damage to the cookies, especially against the background of steatosis and steatohepatitis, which is characteristic for this category of patients.

      1. Елинов Н. П. Химическая микробиология - М.: Высшая школа, 1989. - с 349-365
      2. Шевяков М. А. Кандидоз слизистых оболочек пищеварительного тракта (лекция) // Проблемы медицинской микологии. - 2000. - Т. 2, N 2. - С. 6-10.
      3. Treatment Guidelines for Candidiasis. Pappas et. Al., Clinical Infectious Diseases, 2009, 48:503-535.
      4. Справочник ВИДАЛЬ «Лекарственные препараты в России», Москва, 2016, 22-е издание.
      5. Справочник ЛРС. Регистр Лекарственных средств России. Москва, 2016 г.

    Full text is published :
    Shevyakov M.A. , Uspenskiy Yu.P. FEATURES DIAGNOSIS AND TREATMENT OF CANDIDIASIS OF THE UPPER DIGESTIVE TRACT IN PATIENTS WITH METABOLIC SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;143(07):161-166
    Read & Download full text

    1. Pirogov Russian National Research Medical University (RNRMU) (Moscow, Russian Federation)
    2. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)
    3. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation (Moscow, Russian Federation)

    Keywords:gastroparesis,dopamine receptors,prokinetics,omeprazole,domperidone

    Abstract:The purpose of review: to determine clinical and pharmacological approaches to the choice of gastroparesis therapy. Basic provisions. Prokinetics are medicines that accelerate the movement of content along the digestive tract, affecting dopamine, serotonin, acetylcholine, motilin, cholecystokinin and other receptors. Fixed combination of the proton pump inhibitor and prokinetic proved effective in the therapy of stomach functional disorders. In clinical study on the efficacy and safety of the combination of omeprazole and domperidone sustained release in patients with gastroesophageal reflux disease of mild or moderate severity, according to NNT criteria, it was shown that the drug containing 20 mg omeprazole and 30 mg of domperidone sustained release is very good preparation for the full cupping reflux symptoms (NNT = 2.5), and a good drug for the elimination of esophagitis (NNT = 3,7). It is also shown that this combination is well tolerated (very good and good tolerability at 100 %) and is safe (the frequency of adverse mild degree reactions of 6.7 %, 95 % CI = 0,8-22,1). Conclusion. The use of a combination of omeprazole and domperidone sustained release in gastroparesis is pathogenetically justified. The clinical efficacy and safety of a formulation containing a fixed combination of 20 mg of omeprazole and 30 mg of domperidone sustained release in the treatment of gastroparesis are high.

      1. Алексеева Е. В., Фоминых В. П., Тропская Н. С., Попова Т. С. Применение прокинетика домперидона у больных в раннем послеоперационном периоде // Хирургия. - № 3. - С. 62-69. - 2010
      2. Лазебник Л. Б. Метаболический синдром и органы пищеварения / Л. Б. Лазебник, Л. А. Звенигородская. - М.: Анахарсис, 2009. - 184 с.
      3. Лапина Т.Л, Буеверов А. О. Горечь во рту: интерпретация гастроэнтеролога // Клинические перспективы гастроэнтерологии, 2013, № 3
      4. Маев И. В., Самсонов А. А., Одинцова А. Н., Белявцева Е. В., Задорова М. Г. Перспективы применения нового прокинетика с двойным механизмом действия в терапии гастроэзофагеальной рефлюксной болезни / Фарматека. - 2009. - № 2. - с. 34-39.
      5. Мараховский К.Ю., Василевская С. А., Карасева Г. А., Уласевич Д. Н., Мараховский Ю. Х. Гастроэзофагеальная рефлюксная болезнь: сопоставительная оценка эффективности и безопасности омепразола в комбинации с домперидоном в сравнении с омепразолом. ЛЕЧЕБНОЕ ДЕЛО, No 2 (42), 2015 г. 7-16 /
      6. Саблин О. А. Возможности энтерокинетической терапии нарушений моторики кишечника при запоре // Фарматека. 2013. № 2.
      7. Evaluating the risk of serious ventricular arrhythmia and sud- den cardiac death among users of domperidone. CR 016396 Executive Summary.
      8. A randomized, double-blind, placebo- and positive-controlled, single- and multiple-dose, 4-way crossover study to evaluate the e ects of domperidone on cardiac repolarization in healthy sub- jects. EudraCT number: 2012-001567-70, NCT No.: NCT01643889 // Clin. Reg. No.: CR 100893, Principal Investigator: Katrien Lemmens, MD.
      9. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745-51
      10. Frazee LA, Mauro LS. Erythromycin in the treatment of diabetic gastroparesis. AmJTher 1994; 1: 287-95.
      11. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12th Edition
      12. Hunt JN. Mechanisms and disorders of gastric emptying. Annu rev med 1983; 34: 219-29.
      13. Hunt R H, Camilleri M, Crowe S E, E M El-Omar, J G Fox, E J Kuipers, Malfertheiner P, Mccoll K E L, Pritchard D M, Rugge M, Sonnenberg A, Sugano K, et al. The stomach in health and disease. Gut 2015;64:1650-1668 Doi: 10.1136 / gutjnl-2014-307595
      14. Jin H., Meyer J. M., MudaliarS., and Jeste D. V., Impact of Atypical Antipsychotic Therapy on Leptin, Ghrelin, and Adiponectin. Schizophr Res. 2008 Mar; 100(1-3): 70-85.
      15. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21-34
      16. Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil 2012;24:540-5, e250-1.
      17. Lacy BE, Weiser K. Gastric motility, gastroparesis, and gastric stimulation. Surg clin NORTH AM 2005; 85: 967-vii.
      18. Marakhouski KY, Karaseva GA, Ulasivich DN and Marakhouski Y Kh. Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease. Clinical Medicine Insights: Gastroenterology 2017 V. 10: 1-8
      19. Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104:2779-87.
      20. Mizumoto A, Mochiki E, Suzuki H, Tanaka T, Itoh Z. Neuronal control of motility changes in the canine lower esophageal sphincter and stomach in response to meal ingestion. J smooth muscle res 1997; 33: 211-22.
      21. Moayyedi P, Soo S, Deeks J, et al. Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003; 17: 1215-27
      22. Mohammad MK, Pepper DJ, Kedar A, Bhaijee F, Familoni B, Rashed H, Cutts T, Abell TL. Measures of Autonomic Dysfunction in Diabetic and Idiopathic Gastroparesis. Gastroenterology Res. 2016 Oct;9(4-5):65-69.
      23. Nemecz Á, Prevost MS, Menny A, Corringer PJ. Emerging Molecular Mechanisms of Signal Transduction in Pentameric Ligand-Gated Ion Channels.Neuron. 2016 May 4;90(3):452-70. doi: 10.1016/j.neuron.2016.03.032.
      24. Nutrition and metabolism / edited on behalf of the Nutrition Society by Susan A Lanham-New, Ian Macdonald, Helen Roche. - 2nd ed. 2011
      25. Ortiz A., Cooper Ch. J., Alvarez A., Gomez Y., Sarosiek I., and McCallum RW., Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting.Am J Med Sci 2015;349(5): 421-424
      26. Parkman HP, Hallinan EK, Hasler WL, Farrugia G, Koch KL, Nguyen L, Snape WJ, Abell TL, McCallum RW, Sarosiek I, Pasricha PJ, Clarke J, Miriel L, Tonascia J, Hamilton F; NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterol Motil. 2017 Apr;29(4). doi: 10.1111/nmo.12981. Epub 2016 Oct 25
      27. Patrick A., Epstein O. Gastroparesis. Aliment pharmacol ther. 2008;27(9):724-740
      28. Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans-potential application in the treatment of obesity. Peptides 2011;32:2290-4.
      29. Phillips L. K., Deane A. M., Jones KL., Rayner Ch.K. and Horowitz M. Nat. Rev. Endocrinol. 11, 112-128 (2015)
      30. Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Cochrane Database Syst Rev. 2017 Mar 8;3: CD 011194. doi: 10.1002/14651858.CD 011194.pub2.Proton pump inhibitors for functional dyspepsia.
      31. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463-8.
      32. Preciosa М. et al. Drug-induced acute myocardial infarction: identifying ‘prime suspects’ from electronic healthcare records-based surveillance system / PLoS ONE. 2013; 8 (8): e72148.
      33. Raybould HE, Tache Y. Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats. Am j physiol 1988; 255: g242-246.
      34. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-81
      35. Riezzo G., Russo F., Indrio F. Electrogastrography in Adults and Children: The Strength, Pitfalls, and Clinical Significance of the Cutaneous Recording of the Gastric Electrical Activity / BioMed Res Int. V.2013, Article ID 282757.
      36. Robbins N. M., Ito H., Scheinman M. M., Goadsby P. J. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology® 2016;87:2522-6
      37. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 1998;12:605-12
      38. Tack J, Demedts I, Meulemans A, Schuurkes J, Janssens J. Role of nitric oxide in the gastric accommodation reflex and in meal induced satiety in humans. Gut 2002; 51: 219-24
      39. Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;10:1239-45
      40. Tack J. The physiology and the pathophysiology of the gastric accommodation reflex in man. Verh k acad geneeskd belg 2000; 62: 183-207
      41. Takahashi T, Owyang C. Characterization of vagal pathways mediating gastric accommodation reflex in rats. J physiol1997; 2: 479-488.
      42. Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J gastroenterol 2003; 38: 421-430.
      43. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept. 2009 Jun 5;155(1-3):18-23. doi: 10.1016/j.regpep.2009.03.011. Epub 2009 Apr 2.
      44. Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal transit. Curr gastroenterol rep 2006; 8: 367-373.
      45. Van Roeden S. E. Domperidone and the risk of sudden cardiac death / [et al.] // Ned. Tijdschr. Geneeskd. 2013; 157 (45): A6770.
      46. Soykan I, Ensari A, Karayalcin K. A rare cause of epigastric pain and diarrhea. Gastroenterology. 2014 May;146(5): e1-2. doi: 10.1053/j.gastro.2013.11.041. Epub 2014 Mar 27.

    Full text is published :
    Kareva E.N., Serebrova S.Yu. CHALLENGES IN DRUG TREATMENT OF GASTRIC MOTILITY DISORDERS . Experimental and Clinical Gastroenterology Journal. 2017;143(07):167-183
    Read & Download full text